Biohaven (BHVN) Reports First Patient Enrollment in Phase 3 Generalized Anxiety Disorder Trial Of Troriluzole

February 20, 2019 7:37 AM EST Send to a Friend
Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) today announced that it has enrolled its first patient in a Phase 3 ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to Premium below (Free Trial) LEARN MORE

Member Login